Clinical proteomics towards multiomics in cancer

Area of Science:

• Oncology
• Proteomics
• Genomics

Background:

• Technological advancements in mass spectrometry (MS)-based proteomics have enabled large-scale analysis of human tumor specimens.
• Consortia like the Clinical Proteomic Tumor Analysis Consortium and International Cancer Proteogenome Consortium have generated extensive proteomic and multi-omics data for thousands of human tumors.

Purpose of the Study:

• To review the expanding role of proteomics in cancer research.
• To highlight the potential of existing public proteomic datasets for advancing cancer diagnosis and treatment.
• To explore how public proteomics and multi-omics data from cancer cell lines can identify novel therapeutic strategies.

Main Methods:

• Review of recent literature on MS-based proteomics in cancer research.
• Analysis of publicly available proteomic and multi-omics datasets from human tumors and cancer cell lines.

Main Results:

• Proteomics is crucial for understanding cancer biology at a molecular level.
• Re-analysis of public data can yield new insights and address different research questions.
• Publicly accessible data holds significant promise for clinical applications in cancer care.

Conclusions:

• Proteomics plays a vital and growing role in cancer research and clinical applications.
• Leveraging public proteomic and multi-omics data is key to advancing cancer diagnosis, treatment, and personalized therapy development.